Skip to main content
  • Saved

made a Post

Lemborexant in insomnia disorder: a profile of its use

Lemborexant in insomnia disorder: a profile of its use

Source :

https://link.springer.com/article/10.1007/s40267-020-00771-5

Lemborexant (Dayvigo™), a dual orexin receptor antagonist, is an effective and well-tolerated treatment option for adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. In phase 3 clinical trials, oral lemborexant 5 or 10 mg once nightly significantly reduced sleep onset latency (SOL) and wake-after-sleep onset (WASO), and improved sleep efficiency (SE).